Literature Review Archives

The Future of Systematic Literature Reviews is AI-Assisted, Not AI-Automated

BlogAugust 13, 202664Views 0Likes 0Comments

Overview The future of Systematic Literature Reviews (SLRs) depends on thoughtful integration of technology rather than complete replacement of expert judgment. SLRs remain the foundation for reliable evidence synthesis across healthcare, technology assessment, and policy. The volume of published studies continues to expand, placing heavy demands on research teams that must deliver timely, transparent, and…

$The Hidden Cost of Manual Literature Reviews, and How AI Changes the Math$

The Hidden Cost of Manual Literature Reviews, and How AI Changes the Math

BlogAugust 11, 202662Views 0Likes 0Comments

What Manual Literature Reviews Cost, and Where the Money Goes Manual systematic literature reviews remain the backbone of evidence-based decisions in healthcare, policy, and research. Teams follow strict protocols, search multiple databases, screen thousands of records, extract data by hand, and synthesize findings. The method delivers high-quality results. Yet the true price of this work…

How AI is Cutting Systematic Literature Review Timelines from Months to Days

BlogAugust 7, 202674Views 0Likes 0Comments

Why the Systematic Literature Review Timeline Still Runs Into Months A typical systematic literature review (SLR) timeline is measured in quarters, not weeks, and the reason is rarely a lack of effort. Borah and colleagues tracked reviews registered on PROSPERO and found a median of 67.3 weeks from registration to publication (BMJ Open, 2017). As…

2026 Prediction #5: From Reactive to Proactive Pharmacovigilance with AI

BlogApril 7, 2026262Views 0Likes 0Comments

Imagine a world where drug safety isn’t just about responding to problems after they occur, but it’s about predicting and preventing them before patients are at risk. For decades, traditional pharmacovigilance (PV) has functioned like a fire alarm system: it activates only once the smoke appears. Adverse drug reactions (ADRs) are collected through Individual Case…

2026 Prediction #4: Agentic AI Driving the Next Phase of Continuous Evidence Generation in Pharma

BlogMarch 31, 2026183Views 0Likes 0Comments

For years, the pharmaceutical industry has followed a familiar evidence cycle. Teams design a clinical trial, execute it, lock the database, analyze the results, and wait for another study to address remaining questions. They wait for post-market surveillance to reveal real-world outcomes and for regulators or payers to request additional data before reimbursement decisions. However,…

2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

BlogMarch 25, 2026144Views 0Likes 0Comments

The pharmaceutical industry is currently at a pivotal moment in the AI landscape. After years of cautious AI experimentation limited to isolated labs and pilot programs, something fundamentally different is unfolding in 2026. The central question has shifted from “Does AI work?” to “How do we deploy it safely and at scale?” especially in organizations…

The Future of Systematic Literature Reviews is AI-Assisted, Not AI-Automated

The Hidden Cost of Manual Literature Reviews, and How AI Changes the Math

How AI is Cutting Systematic Literature Review Timelines from Months to Days

2026 Prediction #5: From Reactive to Proactive Pharmacovigilance with AI

2026 Prediction #4: Agentic AI Driving the Next Phase of Continuous Evidence Generation in Pharma

2026 Prediction #3: Role-Based Tool Isolation: The Gold Standard for Secure Pharma AI

Advanced AI Solutions for Life Sciences

Products

Services

By Need

Company

Resources

Connect With Us